DeepMed Research

Rebamipide

Generic Name: Rebamipide

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₅ClN_₂O_₄

CAS Number: 90098-04-7

Unique Ingredient Identifier: LR583V32ZR

Background: Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

Indication: 主要用于胃溃疡，但不宜单独用于Hp感染。也用于改善胃炎及慢性胃炎急性加重期的胃黏膜病变（如糜烂、出血、充血、水肿等）。

Associated Conditions: Gastric Ulcer

Clinical Trials

Evaluation of Topical Rebamipide Versus Topical Betamethasone for Management of Oral Ulcers in Behcet's Disease

Phase 1

Not yet recruiting

Conditions: Oral Ulceration Due to Behçet's Disease

Interventions: Drug: Betamethasone mouthwash
Drug: Rebamipide mouthwash

First Posted Date: 2023-10-16

Last Posted Date: 2023-10-16

Lead Sponsor: Cairo University

Target Recruit Count: 40

Registration Number: NCT06084624

Rebamipide in Patients With Active Rheumatoid Arthritis

Phase 1

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Rebamipide

First Posted Date: 2021-12-21

Last Posted Date: 2024-01-17

Lead Sponsor: October 6 University

Target Recruit Count: 50

Registration Number: NCT05166304

Locations: 🇪🇬
Minia University, Minya, Egypt

Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy

Phase 4

Conditions: Enteritis
Rheumatoid Arthritis
NSAID-Associated Gastropathy
Ankylosing Spondylitis
Other Musculoskeletal Disorder
Gastric Ulcer
Osteoarthritis
NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy

Interventions: Drug: Eupatilin
Drug: Rebamipide

First Posted Date: 2021-05-13

Last Posted Date: 2021-05-13

Lead Sponsor: Seoul National University Boramae Hospital

Target Recruit Count: 50

Registration Number: NCT04885751

Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Nanoparticulated Rebamipide
Drug: Rebamipide
Drug: Clobetasol Propionate

First Posted Date: 2020-12-02

Last Posted Date: 2023-09-21

Lead Sponsor: Cairo University

Target Recruit Count: 39

Registration Number: NCT04649697

Locations: 🇪🇬
Cairo University, Cairo, Egypt

h.Pylori Ttt With Rebamipide

Conditions: H.Pylori Infection

First Posted Date: 2020-09-16

Last Posted Date: 2020-09-16

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT04550858

A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis

Phase 3

Completed

Conditions: Acute Gastritis
Chronic Gastritis

Interventions: Drug: MCT-SR
Drug: Mucosta Tab.

First Posted Date: 2019-12-06

Last Posted Date: 2021-03-11

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 392

Registration Number: NCT04189705

Locations: 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of

To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Rebamipide SR 150mg
Drug: Rebamipide IR 100mg

First Posted Date: 2019-11-04

Last Posted Date: 2019-11-04

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT04150172

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Korea, Republic of

To Evaluate Food Effect on the Pharmacokinetics of Rebamipide in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Rebamipide SR 150mg after high-fat meal
Drug: Rebamipide SR 150mg under fasting condition

First Posted Date: 2019-11-04

Last Posted Date: 2019-11-04

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04150146

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Bundang, Gyeonggi-do, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of AD-203

Phase 3

Completed

Conditions: Acute Gastritis
Chronic Gastritis

Interventions: Drug: AD-203
Drug: Mucosta tab.

First Posted Date: 2019-08-26

Last Posted Date: 2020-12-02

Lead Sponsor: Addpharma Inc.

Target Recruit Count: 475

Registration Number: NCT04066530

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions

Phase 3

Completed

Conditions: Gastric Lesion

Interventions: Drug: 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.
Drug: 550 mg naproxen + placebo + 20 mg rabeprazole
Drug: 550 mg naproxen + placebo + placebo
Drug: 550 mg naproxen + 300 mg rebamipide + placebo

First Posted Date: 2018-09-05

Last Posted Date: 2018-09-05

Lead Sponsor: Galeno Desenvolvimento de Pesquisas Clínicas

Target Recruit Count: 32

Registration Number: NCT03658473

Locations: 🇧🇷
Galeno Desenvolvimento de Pesquisas Clinicas Ltda., Campinas, SP, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy